Dimolegin (dioxaban) / PharmaDiall - LARVOL DELTA

Investigation of the tight binding mechanism of a new anticoagulant DD217 to factor Xa by means of molecular docking and molecular dynamics. (PubMed, J Biomol Struct Dyn) - "The conducted analysis confirms the significant contributions to the MM/GBSA estimated binding free energy of the S4 pocket residues as well the crucial role of establishing the hydrogen bonds between the ligand and the backbone amides of Gly216 and Gly218 of the target. The simulation results support the hypothesis of the tight binding mechanism of DD217 to fXa.Communicated by Ramaswamy H. Sarma."

Journal

A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement (clinicaltrials.gov) - P2 | N=240 | Active, not recruiting | Sponsor: PharmaDiall Ltd. | Trial completion date: Jan 2022 ➔ Dec 2022

Trial completion date • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Venous Thromboembolism